Pharmacy vs. medical benefit

Specialty Pharmacy Section

In 2014, the U.S. drug expenditure was $373.9 billion—the greatest outlay to date—with FDA approving a record-high 44 new medications.1 Of these newly approved drugs, 14 will be covered, mostly under the medical benefit.1

Sixteen (35%) of the drugs approved last year were biologics, 2 were for the treatment of hepatitis C virus, and 8 were cancer medications.1 In addition, a record 18 of the newly approved medications were orphan drugs (used to treat patient populations of fewer than 200,000), with 9 of these qualifying as ultra-orphan drugs (for the treatment of patient populations fewer than 10,000).2

Specialty drugs can be covered under the pharmacy benefit, the medical benefit, or both depending on the benefit design of the payer. The medical benefit specialty drug pipeline is very robust with near-term (2016) oncology agents. Also in this pipeline are medications for hemophilia (which have an extended half-life), muscular dystrophy therapies, and drugs for rare diseases, all of which lend to coverage under the medical benefit.3


In addition, the specialty drugs that are receiving approvals or are in the pipeline are highly effective from a cure rate (hepatitis) or remission rate (cancer) perspective. However, the cost of these drugs remains high, with a 12-week course for hepatitis ranging from $85,000 to $95,000 and orphan drugs for rare chronic diseases costing up to $750,000 per year.4


Payers have been working with their pharmacy benefit managers (PBMs) and specialty pharmacies for more than 10 years to develop and implement programs that provide clinical services to patients who need these medications, as well as management initiatives to assist in controlling costs. Specialty pharmacies establish therapy-specific clinical protocols to ensure that patients are compliant and persistent and to counsel patients on adverse effect management, which is common for these therapies. In addition, specialty pharmacies work with their clients to adopt such cost-controlling management techniques as prior authorizations, preferred products or step therapy, utilization management, and member cost share initiatives.


Specialty drugs that are covered under the pharmacy benefit use national drug codes (NDCs) for billing. These codes provide comprehensive information that identifies the drug, dosage, and package size (number of units). Moreover, NDCs are assigned to a drug when it receives FDA approval. As a result, all of the information needed for both clinical and financial management of the drug/therapy is available.


However, some of these drugs may be covered under the medical benefit; on average, up to 50% of specialty drugs are covered under medical.4  Visibility of these drugs is limited as a result of coding and submission via paper claims rather than electronic submission via the PBM. Medical benefit drugs are coded by J-codes per the Healthcare Common Procedure Coding System. A J-code identifies the chemical name of the drug but is limited in that it does not identify the medication manufacturer, strength, or package size. Other billing limitations of the J-code include the following:


  • Several different drugs may be represented by one J-code. 

  • J-codes do not specify drug quantity dispensed.
  • 
J-codes may not be assigned until up to 18 months after drugs are launched, forcing billing via an unclassified J-code.5

As a result of these limitations, drugs billed using J-codes under the medical benefit are missing necessary information to manage—either from a clinical or cost perspective. There are also additional costs associated with these medications, which require a clinician to administer or to teach the patient self-administration. These costs vary depending on the site of care and are not accounted for in the J-code billing process.


Based on the volume of medications covered under the medical benefit, the difficulty identifying these drugs under the medical benefit, and the associated costs, payers are increasingly collaborating with specialty pharmacies and PBMs to identify management solutions. Solutions vary by disease state but may include preferred products, case management, requiring NDC-level coding on claims, prior authorization, step edit requirements, clinical pathways, and site-of-care management. 
Despite challenges, a significant percentage of specialty drugs will continue to be covered under the medical benefit. An opportunity exists for specialty pharmacies to lead the way in identifying and implementing solutions for all stakeholders to assist in managing specialty drugs from both a clinical and cost-savings perspective.



References

  1. www.forbes.com/sites/bernardmunos/2015/01/02/the-fda-approvals-of-2014/
  2. Medicines use and spending shifts: a review of the use of medicines in the U.S. in 2014
  3. www.magellanrxinsights.com/full-trend-report
  4. http://reports.pbmi.com/report.php
  5. www.managedcaremag.com/archives/0908/0908.specialtydrugcost.html

Forward-Looking Statements


This document contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements give current expectations or forecasts of future events or our future financial or operating performance. The forward-looking statements contained in this document are based on management’s good-faith belief and reasonable judgment based on current information, and these statements are qualified by important risks and uncertainties, many of which are beyond our control, that could cause our actual results to differ materially from those forecasted or indicated by such forward-looking statements. These risks include the number of patients prescribed such drug(s) currently and in the future, patient’s adherence to such drug(s), the number of distributors on panel and our relative distribution share, the timing of drug sales, the cost of such drug(s) and reimbursement rates by payors, drug competition, and the factors set forth in “Risk Factors” in Diplomat’s Annual Report on Form 10-K for the year ended December 31, 2014, and in subsequent reports filed with or furnished to the Securities and Exchange Commission. Except as may be required by any applicable law, Diplomat assumes no obligation to publicly update such forward-looking statements, which are made as of the date hereof or the earlier date specified herein, whether as a result of new information, future developments or otherwise.



Industry and Market Data


Certain information contained in this presentation concerning our industry and the markets in which we operate is based on information from publicly available independent industry and research organizations and other third-party sources, and management estimates. Management estimates are derived from publicly available information released by independent industry and research analysts and third-party sources, as well as data from our internal research, and are based on assumptions made by us upon reviewing such data and our knowledge of such industry and markets, which we believe to be reasonable. We believe the data from these third-party sources is reliable. In addition, projections, assumptions and estimates of the future performance of the industry in which we operate and our future performance are necessarily subject to uncertainty and risk due to a variety of factors, as discussed in Diplomat’s reports filed with the Securities and Exchange Commission. These and other factors could cause results to differ materially from those expressed in the estimates made by these third-party sources


Copyright © 2015 by Diplomat Pharmacy Inc. Diplomat is a registered trademark of Diplomat Pharmacy Inc. All rights reserved.